canyon landscape

Abbvie M21-307

AbbVie / Episodic Migraine: Phase 3 Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine


The purpose of this study is to see if the study drug, BOTOX®, is safe and helps prevent episodic migraines in adults that experience 6-14 migraine days per month and less than 15 headache days per month. This study is for research purposes only. This study will help the sponsor, AbbVie, to learn about BOTOX® safety and effectiveness when compared to placebo (a substance that looks like a drug but has no drug in it) in people experiencing episodic migraines.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor